Daily Stock Analysis, ACRX, AcelRx Pharmaceuticals Inc, priceseries

AcelRx Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
4.20
Close
4.00
High
4.25
Low
3.95
Previous Close
4.17
Daily Price Gain
-0.17
YTD High
4.30
YTD High Date
Jun 18, 2018
YTD Low
1.65
YTD Low Date
Mar 7, 2018
YTD Price Change
1.95
YTD Gain
95.12%
52 Week High
5.75
52 Week High Date
Oct 11, 2017
52 Week Low
1.55
52 Week Low Date
Oct 19, 2017
52 Week Price Change
1.50
52 Week Gain
60.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 14. 2017
2.40
Aug 1. 2017
3.21
12 Trading Days
33.74%
Link
LONG
Mar 8. 2018
1.90
Mar 19. 2018
2.01
7 Trading Days
5.96%
Link
Company Information
Stock Symbol
ACRX
Exchange
NasdaqGM
Company URL
http://www.acelrx.com
Company Phone
650-216-3500
CEO
Vincent J. Angotti
Headquarters
California
Business Address
351 GALVESTON DRIVE, REDWOOD CITY, CA 94063
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Appliances & Equipment
CIK
0001427925
About

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. Its product candidates is comprised of DSUVIA, and ZALVISO, which both contains sufentanil as a therapeutic ingredient. The company was founded by Thomas A. Schreck and Pamela P. Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. The company's late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. Zalviso is approved in the European Union, Switzerland, Liechtenstein, Iceland, Norway and Australia, or the Territory; and is under development stage in the United States. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.